Effect of LPA on the development of MCs from cord blood in serum-free medium in the presence of SCF, IL-6, and IL-10. (A) Cells maintained with the same cytokine triad and standard FCS-containing medium were included for comparison. (B) Data for week 3 in panel A are converted to the percentage of cells with toluidine blue granules in panel B and are the mean ± SEM from 6 separate experiments with cells from different donors. ^*P < .05. (C) Effect of serum delipidation and readdition of LPA on the numbers of total and toluidine blue-positive cells at week 3 of culture in serum-supplemented medium. Data are expressed as the percentage of control (nondelipidated serum supplementation) and are the mean ± half-range for 2 experiments. (D) Histograms depict cell surface Kit expression (unshaded tracings) and negative control antibody (shaded tracings). Data are representative of 4 experiments. (E) RT-PCR analysis of mRNA encoding LPA1R, LPA2R, LPA3R, and GPR23/LPA4R from cord blood-derived hMCs developed for 9 weeks in serum-supplemented medium or for 3 weeks in serum-free medium containing 5 μM LPA. Data are from 1 of 2 representative experiments.